"Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study" by Peter Nash

Article

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Arthritis & Rheumatism (2017)

Peter Nash, University of Queensland
Laura C. Coates, University of Oxford
Alan J. Kivitz, Cedars-Sinai Medical Center
Philip J. Mease, University of Washington
Dafna D. Gladman, Toronto Western Hospital
Jose A. Covarrubias-Cobos
Dona Fleishaker, Pfizer
Cunshan Wang, Pfizer
Elizabeth Kudlacz, Pfizer
Sujatha Menon, Pfizer
Thijs Hendrikx, Pfizer
Keith S. Kanik, National Institutes of Health

Link

Disciplines

Medicine and Health Sciences

Publication Date

October 1, 2017

Citation Information

Peter Nash, Laura C. Coates, Alan J. Kivitz, Philip J. Mease, et al.. "Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study" Arthritis & Rheumatism Vol. 69 (2017)
Available at: http://works.bepress.com/philip-mease/28/